Replies to post #179162 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

The researchers hope that one day these kinds of event-related-potential signatures will be used to characterize outcomes of clinical trials, such that the effectiveness of a treatment can be evaluated by its ability to restore a typical signature.

https://rettsyndromenews.com/2019/01/22/girls-with-rett-syndrome-display-atypical-brain-activity-to-spoken-words-study-finds/

Request that anyone skilled in reading the RSD trial end points do research to note if ERP are measured. Certainly, one would expect trial clinicians and trial-moms to be on top of this. Very small population but possible good set of new information timed conveniently. NICE.